Understanding the Data The data from clinical trials provide insight into the likelihood of experiencing fever while taking semaglutide
Beverly Tchang, an endocrinologist and obesity medicine physician at NewYork-Presbyterian/Weill Cornell Medicine, said she has seen "a tremendous amount of interest" in the drug from patients and "pretty good" insurance coverage of it
Individual results and experiences may vary
In a 10-week clinical trial, a daily dose of 20 mg oral semaglutide achieved a steady-state plasma concentration of 30 nM, and when daily dose of oral semaglutide was increased to 40 mg, the semaglutide plasma concentration reached about 60 nM (102), which was over a thousand times higher than the EC50 of semaglutide for GLP-1R activation (95)
This reduction was accompanied by lower fasting plasma glucose levels and improved insulin sensitivity
Red flags and things to watch for Based on the available information about Zealthy, several areas warrant caution
